Breaking News Instant updates and real-time market news.

VRX

Valeant

$14.39

0.29 (2.06%)

05:12
09/28/17
09/28
05:12
09/28/17
05:12

Valeant provides update on Canadian regulatory filing about financing plans

Valeant Pharmaceuticals routinely evaluates refinancing opportunities, including capital markets transactions, to continue to enhance its capital structure. As part of this, the company filed a routine private placement exemption application with Autorite des marches financiers, the principal securities regulator in Quebec. At this time, no decision has been made with respect to any capital markets transactions. The company does not intend to provide any updates on its financing plans until a definitive decision on any such financing has been made.

  • 02

    Oct

VRX Valeant
$14.39

0.29 (2.06%)

08/17/17
CANT
08/17/17
NO CHANGE
Target $23
CANT
Overweight
Cantor says positive developments at Valeant 'hard to ignore'
In a research note titled "Hard To Ignore All The Positive Developments Coming Out of VRX," Cantor Fitzgerald analyst Louise Chen says the FDA's intention to issue a Voluntary Action Indicated inspection classification for the company's Bausch + Lomb manufacturing facility in Tampa is good news. The development should facilitate the approval of new drugs manufactured out of this facility, Chen tells investors in a research note. She points out that the FDA did not identify any efficacy or safety concerns with respect to the new drug application for Vyzulta, or additional clinical trials needed for the approval. The analyst thinks Vyzulta has the potential to be a blockbuster drug and that manufacturing uncertainties related to current and upcoming regulatory submissions should be eliminated for products manufactured at the Tampa facility. Chen has an Overweight rating on Valeant with a $23 price target. The drugmaker closed yesterday at $14.15.
08/29/17
CANT
08/29/17
NO CHANGE
Target $23
CANT
Overweight
No fundamental reasons for Valeant weakness, says Cantor
Cantor Fitzgerald analyst Louise Chen attributes recent weakness in Valeant shares in part to a civil securities fraud lawsuit that seeks $80B in damages and in part to sell side price target cuts. However, she expects Valeant to vigorously defend itself and believes any resolution would be "significantly less dramatic" than the suit's initial claims. The analyst, who sees no fundamental reasons for the stock's pullback, keeps an Overweight rating and $23 price target on Valeant shares.
08/31/17
RAJA
08/31/17
NO CHANGE
RAJA
Market Perform
Investors wrong to think Fosun will acquire Impax, says Raymond James
Raymond James analyst Elliot Wilbur says shares of Impax Laboratories (IPXL) are up 20% after Shanghai Fosun Pharmaceutical disclosed this morning a 5.19% stake in the company. Investors interpreting the investment as strategic, setting up an eventual takeover of Impax, is inaccurate, Wilbur tells investors in a research note. The analyst points out that Shanghai Fosun has a New York-based investment arm with positions in companies including Valeant Pharmaceuticals (VRX), Dova Pharmaceuticals (DOVA) and Nature's Sunshine Products (NATR). The stake is just a passive investment made because the investment arm of Shanghai Fosun believes in the Impax turnaround story "and nothing more," Wilbur contends. He keeps a Market Perform rating on Impax. The stock in afternoon trading is up 20%, or $3.62, to $21.58.
09/25/17
DBAB
09/25/17
NO CHANGE
Target $19
DBAB
Hold
Valeant 2018 consensus estimates look too high, says Deutsche Bank
Deutsche Bank analyst Gregg Gilbert says 2018 consensus estimates for Valeant Pharmaceuticals look too high after he updated his model to reflect a more conservative view. The analyst now assumes more significant erosion for the company's Dermatology segment and more modest growth for Salix in 2018. His 2018 earnings per share estimate of $3.05 is well below the consensus at $3.54. Gilbert, however, continues to see the potential for "solid" growth beyond 2018, which represents a "trough year" in his model. He keeps a Hold rating on Valeant shares with a $19 price target.

TODAY'S FREE FLY STORIES

NFLX

Netflix

$202.68

3.19 (1.60%)

05:17
10/17/17
10/17
05:17
10/17/17
05:17
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

EQT

EQT Corporation

$62.56

-0.45 (-0.71%)

, RICE

Rice Energy

$27.32

-0.2 (-0.73%)

05:17
10/17/17
10/17
05:17
10/17/17
05:17
Hot Stocks
EQT Corporation reiterates benefits of pending acquisition of Rice Energy »

EQT Corporation (EQT),…

EQT

EQT Corporation

$62.56

-0.45 (-0.71%)

RICE

Rice Energy

$27.32

-0.2 (-0.73%)

EQGP

EQT GP

$29.71

-0.53 (-1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 14

    Nov

  • 15

    May

  • 16

    May

NFLX

Netflix

$202.68

3.19 (1.60%)

05:12
10/17/17
10/17
05:12
10/17/17
05:12
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CMC

Commercial Metals

$20.50

-0.28 (-1.35%)

, GGB

Gerdau

$3.57

-0.01 (-0.28%)

05:11
10/17/17
10/17
05:11
10/17/17
05:11
Upgrade
Commercial Metals, Gerdau rating change  »

Commercial Metals…

CMC

Commercial Metals

$20.50

-0.28 (-1.35%)

GGB

Gerdau

$3.57

-0.01 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SECO

Seeco Holding

$8.30

0.14 (1.72%)

05:07
10/17/17
10/17
05:07
10/17/17
05:07
Initiation
Seeco Holding initiated  »

Seeco Holding initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$198.41

-7.11 (-3.46%)

05:06
10/17/17
10/17
05:06
10/17/17
05:06
Recommendations
Allergan analyst commentary  »

Allergan price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 23

    Oct

  • 01

    Nov

  • 06

    Nov

EV

Eaton Vance

$51.10

0.03 (0.06%)

05:02
10/17/17
10/17
05:02
10/17/17
05:02
Initiation
Eaton Vance initiated  »

Eaton Vance initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FII

Federated Investors

$31.48

0.2 (0.64%)

05:02
10/17/17
10/17
05:02
10/17/17
05:02
Initiation
Federated Investors initiated  »

Federated Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

JHG

Janus Henderson Group

$35.22

-0.08 (-0.23%)

05:01
10/17/17
10/17
05:01
10/17/17
05:01
Initiation
Janus Henderson Group initiated  »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LM

Legg Mason

$37.63

-1.11 (-2.87%)

05:01
10/17/17
10/17
05:01
10/17/17
05:01
Initiation
Legg Mason initiated  »

Legg Mason initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

WETF

WisdomTree

$11.00

0.01 (0.09%)

05:00
10/17/17
10/17
05:00
10/17/17
05:00
Initiation
WisdomTree initiated  »

WisdomTree initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.27

0.52 (3.53%)

04:59
10/17/17
10/17
04:59
10/17/17
04:59
Downgrade
Freeport McMoRan rating change  »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

ERJ

Embraer

$21.42

-0.63 (-2.86%)

, EADSY

Airbus

$22.75

-0.07 (-0.31%)

04:56
10/17/17
10/17
04:56
10/17/17
04:56
Downgrade
Embraer, Airbus rating change  »

Embraer downgraded to…

ERJ

Embraer

$21.42

-0.63 (-2.86%)

EADSY

Airbus

$22.75

-0.07 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$114.58

0.72 (0.63%)

, CSOD

Cornerstone OnDemand

$39.02

0.02 (0.05%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Stephens human capital management team holds analyst/industry conference call »

Enterprise Software…

ADP

ADP

$114.58

0.72 (0.63%)

CSOD

Cornerstone OnDemand

$39.02

0.02 (0.05%)

MSFT

Microsoft

$77.65

0.16 (0.21%)

ORCL

Oracle

$48.86

0.25 (0.51%)

PAYC

Paycom

$78.99

-0.9 (-1.13%)

PCTY

Paylocity

$50.08

0.17 (0.34%)

SAP

SAP

$111.84

-0.88 (-0.78%)

ULTI

Ultimate Software

$194.45

-3.47 (-1.75%)

WDAY

Workday

$107.23

-2.13 (-1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

  • 31

    Oct

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 05

    Nov

  • 08

    Nov

  • 15

    Nov

WES

Western Gas Partners

$50.92

-0.38 (-0.74%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Western Gas Partners to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Stephens food & agribusiness analyst holds an analyst/industry conference call »

Food & Agribusiness…

SFNC

Simmons First National

$58.90

0.45 (0.77%)

, OKSB

Southwest Bancorp

$28.05

0.15 (0.54%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Southwest Bancorp to host special shareholder meeting »

Special Shareholder…

SFNC

Simmons First National

$58.90

0.45 (0.77%)

OKSB

Southwest Bancorp

$28.05

0.15 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 18

    Oct

  • 23

    Oct

CLSD

Clearside Biomedical

$7.77

0.03 (0.39%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Clearside Biomedical management to meet with JMP Securities »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AKR

Acadia Realty Trust

$30.26

-0.2 (-0.66%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Acadia Realty Trust management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 03

    Nov

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Citigroup to hold a conference »

9th Annual Australian…

GSM

Ferroglobe

$14.56

0.39 (2.75%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Ferroglobe to hold investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 14

    Nov

  • 15

    Nov

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Senate Banking, Housing & Urban Affairs Committee to hold a hearing »

The Committee holds a…

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Senate Health, Ed, Labor & Pensions Committee holds a hearing »

The Committee holds a…

MRK

Merck

$63.34

-0.05 (-0.08%)

, GSK

GlaxoSmithKline

$40.86

-0.15 (-0.37%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
European Society of Gene & Cell Therapy will hold a conference »

25th Anniversary Congress…

MRK

Merck

$63.34

-0.05 (-0.08%)

GSK

GlaxoSmithKline

$40.86

-0.15 (-0.37%)

TECH

Bio-Techne

$122.54

0.89 (0.73%)

PLL

Pall Corp.

ICEL

Cellular Dynamics

ABEO

Abeona Therapeutics

$16.70

0.6 (3.73%)

KITE

Acquired by GILD 9/17

PFE

Pfizer

$35.98

-0.36 (-0.99%)

BMRN

BioMarin

$94.66

-0.46 (-0.48%)

SHPG

Shire

$155.28

1.21 (0.79%)

TIG

TiGenix

$24.08

-0.46 (-1.87%)

BIIB

Biogen

$335.68

-1.96 (-0.58%)

QURE

uniQure

$11.98

1.27 (11.86%)

SGMO

Sangamo

$14.85

-0.1 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 18

    Oct

  • 20

    Oct

  • 20

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 31

    Oct

  • 31

    Oct

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

  • 02

    Feb

  • 28

    Feb

  • 17

    Oct

UBS

UBS

, CME

CME Group

$137.52

0.21 (0.15%)

04:55
10/17/17
10/17
04:55
10/17/17
04:55
Conference/Events
Futures Industry Association to hold an expo »

33rd Annual FIA Futures…

UBS

UBS

CME

CME Group

$137.52

0.21 (0.15%)

NDAQ

Nasdaq

$74.11

-0.23 (-0.31%)

ICE

IntercontinentalExchange

$68.40

-0.99 (-1.43%)

CBOE

CBOE Holdings

$109.70

-0.8 (-0.72%)

BAC

Bank of America

$26.24

0.41 (1.59%)

GS

Goldman Sachs

$242.41

3.88 (1.63%)

JPM

JPMorgan

$97.84

1.98 (2.07%)

CS

Credit Suisse

$15.91

0.08 (0.51%)

C

Citi

$71.77

-0.34 (-0.47%)

AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

MS

Morgan Stanley

$48.94

0.64 (1.33%)

WFC

Wells Fargo

$53.80

0.11 (0.20%)

AMTD

TD Ameritrade

$47.77

0.46 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 20

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

  • 02

    Nov

  • 02

    Nov

  • 05

    Nov

  • 07

    Nov

  • 07

    Nov

  • 20

    Nov

  • 29

    Nov

  • 15

    Jan

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.